Literature DB >> 25904754

Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Jacob S Bowers1, Michelle H Nelson2, Sreenath Kundimi2, Stefanie R Bailey2, Logan W Huff2, Kristina M Schwartz2, David J Cole2, Mark P Rubinstein2, Chrystal M Paulos1.   

Abstract

PURPOSE: The adoptive cell transfer (ACT) of CD8(+) T cells is a promising treatment for advanced malignancies. Lymphodepletion before ACT enhances IFNγ(+)CD8(+) T cell (Tc0)-mediated tumor regression. Yet, how lymphodepletion regulates the function and antitumor activity of IL17A(+)CD8(+) T cells (Tc17) is unknown. EXPERIMENTAL
DESIGN: To address this question, pmel-1 CD8(+) T cells were polarized to secrete either IL17A or IFNγ. These subsets were then infused into mice with B16F10 melanoma that were lymphoreplete [no total body irradiation (TBI)], or lymphodepleted with nonmyeloablative (5 Gy) or myeloablative (9 Gy with hematopoietic stem cell transplantation) TBI. The activation of innate immune cells and function of donor T-cell subsets were monitored in recipient mice.
RESULTS: Tc17 cells regress melanoma in myeloablated mice to a greater extent than in lymphoreplete or nonmyeloablated mice. TBI induced functional plasticity in Tc17 cells, causing conversion from IL17A to IFNγ producers. Additional investigation revealed that Tc17 plasticity and antitumor activity were mediated by IL12 secreted by irradiated host dendritic cells (DC). Neutralization of endogenous IL12 reduced the antitumor activity of Tc17 cells in myeloablated mice, whereas ex vivo priming with IL12 enhanced their capacity to regress melanoma in nonmyeloablated animals. This, coupled with exogenous administration of low-dose IL12, obviated the need for host preconditioning, creating curative responses in nonirradiated mice.
CONCLUSIONS: Our findings indicate that TBI-induced IL12 augments Tc17 cell-mediated tumor immunity and underline the substantial implications of in vitro preparation of antitumor Tc17 cells with IL12 in the design of T-cell immunotherapies. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25904754      PMCID: PMC4452402          DOI: 10.1158/1078-0432.CCR-14-2294

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation.

Authors:  Naofumi Takemoto; Andrew M Intlekofer; John T Northrup; E John Wherry; Steven L Reiner
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

Review 3.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

Review 4.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

5.  Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells.

Authors:  Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher
Journal:  Science       Date:  2002-01-11       Impact factor: 47.728

6.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

7.  Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Authors:  Yu Yu; Hyun-Ii Cho; Dapeng Wang; Kane Kaosaard; Claudio Anasetti; Esteban Celis; Xue-Zhong Yu
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

8.  IL-23 promotes maintenance but not commitment to the Th17 lineage.

Authors:  Gretta L Stritesky; Norman Yeh; Mark H Kaplan
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  14 in total

1.  The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.

Authors:  Aditya Arra; Holger Lingel; Benno Kuropka; Jonas Pick; Tina Schnoeder; Thomas Fischer; Christian Freund; Mandy Pierau; Monika C Brunner-Weinzierl
Journal:  Oncoimmunology       Date:  2017-01-20       Impact factor: 8.110

2.  Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.

Authors:  Daniel J Neitzke; Jacob S Bowers; Kristina Andrijauskaite; Nathaniel S O'Connell; Elizabeth Garrett-Mayer; John Wrangle; Zihai Li; Chrystal M Paulos; David J Cole; Mark P Rubinstein
Journal:  Cancer Immunol Immunother       Date:  2017-03-09       Impact factor: 6.968

3.  IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors.

Authors:  Andreas Hombach; Markus Barden; Lisa Hannappel; Markus Chmielewski; Gunter Rappl; Agapios Sachinidis; Hinrich Abken
Journal:  Mol Ther       Date:  2021-10-19       Impact factor: 11.454

4.  Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.

Authors:  Jacob S Bowers; Michelle H Nelson; Kinga Majchrzak; Stefanie R Bailey; Baerbel Rohrer; Andrew Dm Kaiser; Carl Atkinson; Luca Gattinoni; Chrystal M Paulos
Journal:  JCI Insight       Date:  2017-03-09

Review 5.  Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Authors:  Kinga Majchrzak; Michelle H Nelson; Stefanie R Bailey; Jacob S Bowers; Xue-Zhong Yu; Mark P Rubinstein; Richard A Himes; Chrystal M Paulos
Journal:  Cancer Immunol Immunother       Date:  2016-01-29       Impact factor: 6.968

6.  Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Authors:  Mireia Uribe-Herranz; Kyle Bittinger; Stavros Rafail; Sonia Guedan; Stefano Pierini; Ceylan Tanes; Alex Ganetsky; Mark A Morgan; Saar Gill; Janos L Tanyi; Frederic D Bushman; Carl H June; Andrea Facciabene
Journal:  JCI Insight       Date:  2018-02-22

7.  Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

Authors:  Mireia Uribe-Herranz; Stavros Rafail; Silvia Beghi; Luis Gil-de-Gómez; Ioannis Verginadis; Kyle Bittinger; Sergey Pustylnikov; Stefano Pierini; Renzo Perales-Linares; Ian A Blair; Clementina A Mesaros; Nathaniel W Snyder; Frederic Bushman; Constantinos Koumenis; Andrea Facciabene
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 19.456

Review 8.  Harnessing the Microbiome to Enhance Cancer Immunotherapy.

Authors:  Michelle H Nelson; Marshall A Diven; Logan W Huff; Chrystal M Paulos
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

9.  IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors.

Authors:  Hannah M Knochelmann; Connor J Dwyer; Aubrey S Smith; Jacob S Bowers; Megan M Wyatt; Michelle H Nelson; Guillermo O Rangel Rivera; Joshua D Horton; Carsten Krieg; Kent Armeson; Gregory B Lesinski; Mark P Rubinstein; Zihai Li; Chrystal M Paulos
Journal:  Cancer Res       Date:  2020-06-19       Impact factor: 12.701

10.  Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.

Authors:  Michelle H Nelson; Jacob S Bowers; Stefanie R Bailey; Marshall A Diven; Caroline W Fugle; Andrew D M Kaiser; Claudia Wrzesinski; Bei Liu; Nicholas P Restifo; Chrystal M Paulos
Journal:  J Immunother Cancer       Date:  2016-02-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.